Heart failure & cardiomyopathiesSecondary analysis
Proteomic Profiles of Left Atrial Volume and Its Influence on Response to Spironolactone: Findings from the HOMAGE Trial and STANISLAS Cohort
- Secondary analysis of the HOMAGE randomised trial with external replication in the STANISLAS population-based cohort
Authors' conclusion
In individuals without heart failure, LAVi was associated with MMP-2, IGFBP-2 and NT-proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size.
Study context
- Population
- People at risk of HF (HOMAGE); asymptomatic individuals from a population-based cohort (STANISLAS)HOMAGE analysed
- Participants
- 421 people
- Comparison
- Spironolactone vs control; association of LAVi with circulating proteins
- Primary endpoint
- Clinical and proteomic characteristics associated with LAVi, and whether LAVi influences response to spironolactone
Primary result
As reported in the abstract
Proteins associated with greater LAVi (HOMAGE)
Greater LAVi associated with higher MMP-2, IGFBP-2 and NT-proBNP after adjustment and multiple-testing correction
FDR <0.05
Associations externally replicated in STANISLAS
all FDR <0.05
Further findings
Effect of spironolactone on MMP-2 and NT-proBNP, by baseline LAVi
- Spironolactone decreased MMP-2 and NT-proBNP regardless of baseline LAVi
- P for interaction > 0.10
Effect of spironolactone on LAVi, LVEF, E/e', BP and PICP
- Spironolactone significantly reduced LAVi, improved LVEF, lowered E/e', BP and PICP regardless of baseline LAVi
- P for interaction > 0.10
Original publication
Proteomic Profiles of Left Atrial Volume and Its Influence on Response to Spironolactone: Findings from the HOMAGE Trial and STANISLAS Cohort. Eur J Heart Fail. Published 25 March 2024. doi:10.1002/ejhf.3202
Summarised from the published abstract; every number is checked against it